last year's earnings conference call was held on August 4th, so I suspect later this month Curis will issue a press release announcing call in early August. That date would qualify as early 3rd quarter, the time period Curis is committed to disclosing its interim analysis regarding data on Ph2 907. Right now volume is extremely low so any bad news would be devastating as buyers would be hard to come by. I have got my fingers crossed Cris will finally have something positive to say about 907's prospects getting to market. The bigger news regarding CA-170 ph1 data comes later in the quarter.
price of stock irrelevant until release of interim data on 907 Ph2 trial. Issue is whether data is sufiicient and is it positive enough for Cris to go to FDA for permission to convert ongoing Ph2 trial to a pivotal one which would mean expanding current population of 60 to 100 plus. Aurigene must be sweating their investment at this point as, if 907 fails, where does Cris go for more money for Aurigene small molecule trials?
ugly day for CRIS chartwatchers
Folks was in CRIS for a long time and lost big...learning the hard way about this co. Just throwing it out there learn, about Pieris Pharmaceuticals, PIRS. It has begun a ramp price wise, but is still very much unknown to the investment community BUT not the big pharmas, Go to their site and just give it a read. No spamming just lending a helping hand to fellow suffers of this unfortunate company. Anticalin proteins will be huge in many diseases and they own the technology. Just a fyi. gl in whatever you do.
Earnings conference early August; my hunch is that we will know by then interim data on Ph2 907 trial. Of 60 patients, hopefully 30 are evaluable; of those 30, ORR has got to be in 30 to 40% range and durability of cliinical benefit not less than 6 months. That would be sufficient I believe to get FDA to convert PH2 to pivotal. It's been four and a half years since first dosage of Ph1 of this trial; they must have a prettty good idea by now whether 907 can clinically benefit patients with Myc-altered RR DLBCL .
X axis : Stocks Price Correlation Coefficient Y axis : Quantity of stocks May-2016 1,000 Day Parameter 2,830 NASDAQ Stocks Price Analysis This stock mode of correlation coefficient is -0.6 In other words, the correlation coefficient of the other stoc
Ali- You are a waste How does this BOD have any respect for themselves
They suk equally
"If Roche opts to partner for I-O combo w/Tecentriq, CRIS will hit 7.50" Does anyone know what this comment on Twitter means? Does Cris' Erivedge collaboration with Roche have anything to do with Roche's development of Tecentriq?
Buy some shares you worthless camel toe CEO!!!!!!!
Nine days to go until expiration of period during 907 Ph2 trial at which time Curis hopefully will have sufficiently positive data to make its pitch to FDA for conversion to pivotal trial.
Red hot aveo .... ck out AVEO now.
9:05 Small Molecule Antagonists of Immune Checkpoint Pathways Pottayil_SasikumarPottayil G. Sasikumar, Ph.D., Associate Research Director, Medicinal Chemistry, Aurigene Discovery Technologies Ltd. Immune checkpoint antibodies have revolutionized cancer therapy because of their impressive clinical activity. However, they suffer from the shortcomings including the failure to show response in a majority of patients, need to administer by intravenous injection and immune-related adverse events. We are developing small molecule immune checkpoint antagonists that do not exhibit these limitations. CA-170, a candidate from this approach dually targeting PD-L1 and VISTA is now undergoing clinical trials.
Wow! New Corporate presentation in the web site (June). We can read in the page 8:
Study Ongoing - Based on results, potential for discussion with FDA for accelerated registration path - Enrolling in 25 centers in the US and Europe - RESPONSES HAVE BEEN OBSERVED - Preliminary study read-out in Q3 2017
I think these are nice words... "read between lines..."
David Tuck speaking on June 13th; last time he spoke regarding Ph1 370 trial in November, stock soared, so if Ali has nothing much to say tomorrow, maybe Tuck will at the World Preclinical Congress. I am getting desperate for a catalyst.
10:50 Development, Discovery and Details of the Oral Small Molecule Checkpoint Inhibitors, CA170 and CA327 David Tuck, M.D., CMO, Curis, Inc. CA-170 is a first-in-class, orally-available, small molecule antagonist of the immune checkpoints PD-L1 and VISTA. CA-170 is currently undergoing investigation in a Phase I clinical trial in patients with advanced solid tumors and lymphoma. CA-327 is a first-in-class, orally-available, small molecule antagonist of the immune checkpoints PD-L1 and TIM3. CA-327 is currently undergoing IND-enabling studies, and the company expects to file an IND and initiate clinical testing of CA-327 in 2017.
Explain me ! Explain me ! Friday + 0,18 cents. Monday -0,18 cents. ASCO expectations? No my God. Welcome to the Casino and good luck.
Monster MicroCaps Research Alert to CRIS shareholders. Clean energy Technologies (CETY) is under 2 pennies with a market cap of under $4 million and just announced it is expanding operations and marketing by opening Sales & Service Center in Europe to serve the current 65 HRS (Heat Recovery Systems) installations and to expand sales in Europe.
CETY technology was purchased from General Electric in 2015 and is attractive to huge unmet markets that can achieve over $250 million annual sales within the next 2 to 3 years. Demand for conversion of wasted heat to electrical energy in large applications is very large and unmet!
Each CETY HRS (Heat Recovery System) sells for about $300,000.
Clean Energy Technologies, Inc. Establishes CETY Europe Sales and Service Center
COSTA MESA, Calif., June 1, 2017 /PRNewswire/ -- Clean Energy Technologies, Inc. (OTC: CETY) announced today that it has established a new CETY Europe Sales and Service Center in Silea (Treviso), Italy. ...
CRIS stock in 6 months? 👍👎
CRIS appears to suggest upside opportunity. have you guys heard of awe.some.stocks. i started receiving their allerts and so far i am happy.
It is not easy the life of CRIS. Nice jump yesterday at close with good volume. Nice jump today at open with nice volume again. But it seems today some fund are adjusting his position considering today it is the May close. 1M shares traded at 1.69-1.81 range... and we are there, in the minimun.
buying AXSM at $4 is like buying JAZZ at $1 a few years ago now trading at $151 (AXSM) Market Cap $90 M/Cash $55 M / 5x BIG Phase 3 programs in various indications targeting large Markets with first results in Q3 2017 =20 BAGGER ..FANTASTIC OPPORTUNITY !
Undiscovered and massive undervalued Biotech Stock with lots of Big News on the way.This Stock is brutally undervalued with a Market cap of just $90 million and $55 million in cash .Founder and Ceo is the larget shareholder holding over 7 million shares (30%) more than 50% of O/S is owned by Insider and Institutions which is a great sign .
This undiscovered stock could be the next 10 bagger gem if just one of their 5 ongoing Phase 3 programs is successful .GL
Market-Cap: $90 Million Cash: $55 Million(cash runway into the first quarter of 2019.) Price:$3.90
Shares Out: 23.5 Million
Aegis Capital has reiterated a ‘Buy’ rating and price target of $20 on Axsome Therapeutics (NASDAQ: AXSM) after the company reported financial results for the quarter ended March 31, 2017. The analyst noted that although Axsome reported revenue in-line with consensus estimates, the focus remains on upcoming catalysts such as the company’s ongoing clinical trials. Since February 2017, the company’s AXS-05 has received fast track designation from the FDA for the treatment of Alzheimer’s disease (AD) agitation and treatment resistant depression (TRD). Topline data from the TRD treatment study is expected in the first quarter of 2018. Additionally, Axsome is developing AXS-02 in three separate phase 3 clinical programs, including chronic low back pain associated with modic changes and complex regional pain syndrome, with interim data expected in the fourth quarter of 2017, as well as knee osteoarthritis associated with bone marrow lesions, with interim data expected in the third quarter of 2017.